Loading...

APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
505809 25 µg 36€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  3. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  6. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  7. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  8. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  9. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  10. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  11. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  12. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  13. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  14. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  15. Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed
  16. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  17. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  18. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  19. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  20. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  21. Qu L, et al. 2022. Cell. 185:1728. PubMed
  22. Grebinoski S, et al. 2022. Nat Immunol. 23:868. PubMed
  23. Guo X, et al. 2022. Invest Ophthalmol Vis Sci. 63:12. PubMed
  24. Blanas A, et al. 2022. iScience. 25:104719. PubMed
  25. Gary EN, et al. 2022. Cell Rep Med. 3:100693. PubMed
  26. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  27. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  28. Balood M, et al. 2022. Nature. 611:405. PubMed
  29. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  30. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  31. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  32. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  33. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  34. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  35. Xiao J, et al. 2023. J Clin Invest. 133: . PubMed
  36. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  37. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  38. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  39. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  40. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  41. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  42. Tao X, et al. 2022. J Exp Med. 219:. PubMed
  43. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  44. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  45. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  46. Wang Z, et al. 2022. J Control Release. 349:929. PubMed
  47. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  48. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  49. Shi X, et al. 2023. iScience. 26:106143. PubMed
  50. Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed
  51. Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed
  52. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  53. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  54. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  55. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  56. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  57. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  58. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  59. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  60. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  61. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  62. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  63. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  64. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  65. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  66. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  67. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  68. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  69. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  70. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  71. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  72. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  73. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  74. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  75. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  76. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  77. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  78. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  79. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  80. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  81. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  82. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  83. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  84. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  85. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  86. Diao L, et al. 2022. iScience. 25:105511. PubMed
  87. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  88. Gu M, et al. 2021. Nat Immunol. 22:193. PubMed
  89. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  90. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  91. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  92. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  93. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  94. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  95. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  96. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  97. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  98. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  99. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  100. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  101. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  102. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  103. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  104. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  105. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  106. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  107. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  108. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  109. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  110. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  111. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  112. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  113. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  114. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  115. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  116. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  117. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  118. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  119. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  120. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  121. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  122. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  123. Mills C, et al. 2022. Cells. 11:. PubMed
  124. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  125. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  126. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  127. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  128. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  129. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  130. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  131. Harty J 2009. Infect Immun. 77:1894. PubMed
  132. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  133. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  134. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  135. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  136. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  137. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  138. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  139. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  140. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  141. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  142. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  143. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  144. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  145. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  146. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  147. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  148. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  149. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  150. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  151. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  152. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  153. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  154. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  155. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  156. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  157. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  158. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  159. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  160. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  161. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  162. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  163. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  164. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  165. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  166. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  167. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  168. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  169. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  170. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  171. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  172. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  173. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  174. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  175. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  176. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  177. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  178. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  179. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  180. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  181. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  182. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  183. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  184. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  185. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  186. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  187. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  188. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  189. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  190. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  191. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  192. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  193. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  194. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  195. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  196. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  197. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  198. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  199. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  200. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  201. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  202. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  203. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  204. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  205. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  206. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  207. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  208. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  209. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  210. Gupta S, et al. 2022. Life Sci. 288:120182. PubMed
  211. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  212. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  213. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  214. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  215. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  216. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  217. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  218. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  219. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  220. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  221. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  222. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  223. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  224. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  225. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  226. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  227. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  228. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  229. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  230. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  231. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  232. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  233. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  234. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  235. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  236. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  237. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  238. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  239. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  240. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  241. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  242. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  243. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  244. Sheng J, et al. 2021. eLife. 10:00. PubMed
  245. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  246. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  247. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  248. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  249. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  250. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  251. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  252. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  253. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  254. Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed
  255. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  256. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  257. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  258. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  259. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  260. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  261. Yang L, et al. 2021. Front Immunol. 12:722273. PubMed
  262. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  263. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
  264. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  265. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  266. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  267. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
  268. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  269. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  270. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315403 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account